ATRIUM THERAPEUTICS INC (RNA) Fundamental Analysis & Valuation

NASDAQ:RNA • US05370A1088

14.07 USD
-0.47 (-3.23%)
Last: Mar 13, 2026, 12:09 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, RNA scores 4 out of 10 in our fundamental rating. RNA was compared to 519 industry peers in the Biotechnology industry. While RNA has a great health rating, there are worries on its profitability. RNA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. RNA Profitability Analysis

1.1 Basic Checks

  • RNA had negative earnings in the past year.
  • In the past year RNA has reported a negative cash flow from operations.
  • In the past 5 years RNA always reported negative net income.
  • In the past 5 years RNA always reported negative operating cash flow.
RNA Yearly Net Income VS EBIT VS OCF VS FCFRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • RNA has a Return On Assets of -25.76%. This is in the better half of the industry: RNA outperforms 69.75% of its industry peers.
  • RNA's Return On Equity of -29.15% is fine compared to the rest of the industry. RNA outperforms 75.72% of its industry peers.
Industry RankSector Rank
ROA -25.76%
ROE -29.15%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
RNA Yearly ROA, ROE, ROICRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

  • RNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNA Yearly Profit, Operating, Gross MarginsRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RNA Health Analysis

2.1 Basic Checks

  • RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RNA has more shares outstanding
  • RNA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNA Yearly Shares OutstandingRNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RNA Yearly Total Debt VS Total AssetsRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • RNA has an Altman-Z score of 4.64. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.64, RNA is doing good in the industry, outperforming 71.29% of the companies in the same industry.
  • There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.64
ROIC/WACCN/A
WACC8.85%
RNA Yearly LT Debt VS Equity VS FCFRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • RNA has a Current Ratio of 11.57. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RNA (11.57) is better than 85.55% of its industry peers.
  • RNA has a Quick Ratio of 11.57. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 11.57, RNA belongs to the best of the industry, outperforming 85.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.57
Quick Ratio 11.57
RNA Yearly Current Assets VS Current LiabilitesRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RNA Growth Analysis

3.1 Past

  • RNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.14%.
  • Looking at the last year, RNA shows a very strong growth in Revenue. The Revenue has grown by 106.27%.
  • Measured over the past years, RNA shows a very strong growth in Revenue. The Revenue has been growing by 36.26% on average per year.
EPS 1Y (TTM)-45.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-95.38%
Revenue 1Y (TTM)106.27%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%434.03%

3.2 Future

  • Based on estimates for the next years, RNA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.33% on average per year.
  • RNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 177.45% yearly.
EPS Next Y-57.4%
EPS Next 2Y-34.08%
EPS Next 3Y-14.9%
EPS Next 5Y29.33%
Revenue Next Year134.19%
Revenue Next 2Y66.31%
Revenue Next 3Y223.76%
Revenue Next 5Y177.45%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RNA Yearly Revenue VS EstimatesRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RNA Yearly EPS VS EstimatesRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RNA Valuation Analysis

4.1 Price/Earnings Ratio

  • RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNA Price Earnings VS Forward Price EarningsRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNA Per share dataRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as RNA's earnings are expected to decrease with -14.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.08%
EPS Next 3Y-14.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RNA Dividend Analysis

5.1 Amount

  • RNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RNA Fundamentals: All Metrics, Ratios and Statistics

ATRIUM THERAPEUTICS INC

NASDAQ:RNA (3/13/2026, 12:09:22 PM)

14.07

-0.47 (-3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-03
Inst OwnersN/A
Inst Owner Change-5.84%
Ins OwnersN/A
Ins Owner Change1.88%
Market Cap2.18B
Revenue(TTM)20.87M
Net Income(TTM)-549.79M
Analysts67.78
Price Target74.07 (426.44%)
Short Float %6.93%
Short Ratio3.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.79%
Min EPS beat(2)-21.39%
Max EPS beat(2)-14.2%
EPS beat(4)1
Avg EPS beat(4)-8.77%
Min EPS beat(4)-21.39%
Max EPS beat(4)0.55%
EPS beat(8)3
Avg EPS beat(8)-3.28%
EPS beat(12)7
Avg EPS beat(12)1.34%
EPS beat(16)9
Avg EPS beat(16)0.21%
Revenue beat(2)2
Avg Revenue beat(2)324.5%
Min Revenue beat(2)158.88%
Max Revenue beat(2)490.11%
Revenue beat(4)3
Avg Revenue beat(4)181.01%
Min Revenue beat(4)-18.03%
Max Revenue beat(4)490.11%
Revenue beat(8)4
Avg Revenue beat(8)76.22%
Revenue beat(12)8
Avg Revenue beat(12)57.88%
Revenue beat(16)10
Avg Revenue beat(16)42.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)0%
EPS NY rev (3m)1.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)14.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 104.33
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-4.18
EYN/A
EPS(NY)-5.2
Fwd EYN/A
FCF(TTM)-3.85
FCFYN/A
OCF(TTM)-3.75
OCFYN/A
SpS0.13
BVpS12.19
TBVpS12.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.76%
ROE -29.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 439.11%
Cap/Sales 71.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.57
Quick Ratio 11.57
Altman-Z 4.64
F-Score3
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-95.38%
EPS Next Y-57.4%
EPS Next 2Y-34.08%
EPS Next 3Y-14.9%
EPS Next 5Y29.33%
Revenue 1Y (TTM)106.27%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%434.03%
Revenue Next Year134.19%
Revenue Next 2Y66.31%
Revenue Next 3Y223.76%
Revenue Next 5Y177.45%
EBIT growth 1Y-88.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.16%
EBIT Next 3Y-17.56%
EBIT Next 5YN/A
FCF growth 1Y-232.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-232.19%
OCF growth 3YN/A
OCF growth 5YN/A

ATRIUM THERAPEUTICS INC / RNA FAQ

Can you provide the ChartMill fundamental rating for ATRIUM THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to RNA.


What is the valuation status of ATRIUM THERAPEUTICS INC (RNA) stock?

ChartMill assigns a valuation rating of 0 / 10 to ATRIUM THERAPEUTICS INC (RNA). This can be considered as Overvalued.


Can you provide the profitability details for ATRIUM THERAPEUTICS INC?

ATRIUM THERAPEUTICS INC (RNA) has a profitability rating of 1 / 10.


What is the financial health of ATRIUM THERAPEUTICS INC (RNA) stock?

The financial health rating of ATRIUM THERAPEUTICS INC (RNA) is 8 / 10.


Can you provide the expected EPS growth for RNA stock?

The Earnings per Share (EPS) of ATRIUM THERAPEUTICS INC (RNA) is expected to decline by -57.4% in the next year.